Navigation Links
Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
Date:6/5/2008

- Phase II Data Indicate Overall and Disease-Free Survival -

WAYNE, N.J., June 5 /PRNewswire/ -- Results from an adjuvant trial in high-risk melanoma patients demonstrated that a majority of patients treated with Leukine(R) (sargramostim) achieved disease-free and/or overall survival. These findings, which indicate Leukine's potential in this cancer setting, were released at the 44th annual meeting of the American Society of Clinical Oncology (ASCO).

Results from the Phase II study (ASCO abstract #20027) show that 60 percent of the 45 high-risk patients enrolled in the trial experienced disease-free survival and 64 percent of patients achieved overall survival at 21 months.

"Previous findings suggest that sargramostim may be a potential adjuvant therapy for high-risk melanoma patients," said E. George Elias M.D., Ph.D., Director of Maryland Melanoma Center. "The percentage of patients who achieved disease-free and overall survival in this trial provides further evidence that sargramostim may prove to be a viable treatment option for this patient population and that further study in Phase III trials are needed."

In this trial, adjuvant therapy with Leukine and a synergistic cytokine, IL-2, was generally well-tolerated in patients with high-risk melanoma following potentially curative surgery. Each patient received two years of adjuvant therapy: year one with Leukine and IL-2 and year two with only Leukine. Toxicities were mild to moderate and no hospitalizations were required.

"These data, particularly the overall survival rates, are encouraging, even though preliminary, and indicate Leukine's potential as a treatment in this setting," said Paul MacCarthy, M.D., FRCPI, vice president and head of U.S. Medical Affairs for Bayer HealthCare Pharmaceuticals.

Clinical Trial Overview

This Phase II trial was a single-arm, open-labeled study to evaluate the safety, tolerability and treatment efficacy of Leukine and I
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
2. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
3. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
4. Wound Management Technologies, Inc. Announces Evidence Based Study
5. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
6. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
7. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Study Findings Show Infection Control Intervention Helps Keep Kids in School
10. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
11. Study Finds Disparities in Breast Cancer Treatment Even Among Fully-Insured African-American and Caucasian Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "Global Hypodermic Needles Market 2014-2018" report to ... A hypodermic needle is a hollow needle ... the body or or to extract fluids from it. ... liquids or to inject substances that cannot be ingested. ...
(Date:7/11/2014)... , July 11, 2014 Research and ... of the "Immunoprotein Diagnostic Testing Market - ... highest CAGR of 6% and is expected to ... to their offering. ... diagnostic testing has been segmented according to immunoprotein ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... NEW YORK, Jan. 25, 2011 Reportlinker.com ... is available in its catalogue: ... analysis of small molecule brand erosion post-patent ... IntroductionPharma is facing slowing ...
... 2011 Prolong Pharmaceuticals, which in October secured a ... today announced the signing of a long term lease ... and the formal addition of Dr. Hemant Misra to ... and Facilities Operations. The manufacturing facility ...
Cached Medicine Technology:Reportlinker Adds Brand Erosion Post-Patent Expiry - An analysis of small molecule brand erosion post-patent expiry 2Prolong Pharmaceuticals Leases 24,000-Square-Foot Manufacturing Facility, Adds Facilities Veteran to Executive Team 2
(Date:7/12/2014)... As reported in this July 1st article ... the June 25th, 2014 Supreme Court ruling in Riley v ... It was also met with both cheers and jeers when ... seen from an individual privacy perspective, or a law enforcement ... now precedent which will require law enforcement officials to obtain ...
(Date:7/12/2014)... July 12, 2014 Praeclarus Press ... Simple as a valuable new resource for women in ... of American women work away from their children. Today’s ... the benefits of breastfeeding, but often feel unsupported when ... their babies. With its evidence-based insights, and written by ...
(Date:7/12/2014)... Palm Beach, FL (PRWEB) July 12, 2014 ... variety of high-quality peptides that are used solely in ... To honor two successful years in business, Maxim Peptide, ... LLC, has just launched a new and updated website ... the research blog section has been updated with fascinating ...
(Date:7/11/2014)... 2014 Recently, DressyQuinceanera.com, a well-known wedding ... Dama dresses to its online category. Furthermore, the ... at deeply discounted rates, up to 62% off. , ... equally excellent in terms of quality and style. All ... discounts are also offered for the company’s other items: ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 As ... filed against Johnson & Johnson’s Ethicon Inc. unit ... LLP notes that the Texas Attorney General’s Office ... marketing of surgical mesh products used to treat ... to a report from kens5.com, the probe began ...
Breaking Medicine News(10 mins):Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:DressyQuinceanera.com: Beautiful Quinceanera Dama Dresses At Low Prices 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4
... By Jenifer Goodwin HealthDay Reporter , FRIDAY, ... temporarily zaps away forehead wrinkles by freezing the nerves ... The technique, if eventually approved by the U.S. Food ... and Dysport. Both are injectable forms of Botulinum toxin ...
... April 2011: Exciting new data presented today at the ... chronic hepatitis C (HCV) patients suppressed the emergence of ... sustained virological response - undetectable HCV RNA - 12 ... study, HCV patients were given four drugs in combination; ...
... on the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer ... and presented updated results at the AACR 102nd Annual ... Heymach, M.D., Ph.D., associate professor of thoracic, head and neck ... Center, said this update details the "discovery phase" of the ...
... April 1 (HealthDay News) -- It,s important to keep injury ... Dr. Steven Greer, of the MCGHealth Sports Medicine Center in ... children. All children should undergo a physical examination before ... an extended period of time, they should begin increasing ...
... April 1 (HealthDay News) -- Updated guidelines to keep children ... released this week by the American Academy of Pediatrics. ... interests, skills and overall well-being, to ensure their child can ... to medically and mentally prepare their child for camp, and ...
... scientific discoveries in children,s health will be presented in Denver ... the Pediatric Academic Societies (PAS). This year,s gathering is a ... and more than 6,500 leaders in academic pediatrics from around ... Colorado Convention Center. Journalists will have access to ...
Cached Medicine News:Health News:Freezing Wrinkles a Possible Alternative to Botox 2Health News:Freezing Wrinkles a Possible Alternative to Botox 3Health News:Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment 2Health News:BATTLE researchers identify new biomarkers for EGFR inhibition 2Health News:Tips for Keeping Young Athletes Safe 2Health News:Pediatrics Group Offers Guidelines to Keep Young Campers Safe, Healthy 2Health News:Children's health is focus of annual meeting of Pediatric Academic Societies 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: